Fosamax and Osteonecrosis of the Jaw: Understanding Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy Context: General Health and Science Information

For decades, general health and science information has served as the foundation for public understanding of medication safety and bone health. Within this legacy context, broad educational resources have consistently emphasized the importance of informed patient-provider communication regarding prescription therapies. The transition from this general health framework to a more specialized occupational exposure concern begins with recognizing that certain medications, originally developed to address systemic bone conditions, may present distinct risk profiles in specific populations. In the domain of mass production, particularly within pharmaceutical manufacturing and healthcare settings, workers may encounter concentrated forms of active pharmaceutical ingredients during handling and processing. This occupational context shifts the focus from patient-centered therapeutic use to potential workplace exposure scenarios.

Bridge Transition: From General Awareness to Targeted Inquiry

The bridge concept here involves moving from a general awareness of medication-related health considerations to a targeted examination of how industrial exposure to bisphosphonate compounds—such as those found in Fosamax—could relate to oral health complications, specifically osteonecrosis of the jaw. This pivot does not assert causation but rather establishes a logical progression: from broad health literacy about bone therapies to a focused inquiry into occupational safety protocols for those who handle these substances in mass production environments. The concern centers on exposure routes, duration, and concentration levels distinct from therapeutic dosing.

Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is characterized by exposed bone in the oral cavity that does not heal within eight weeks of identification. The condition can occur spontaneously but is generally associated with tooth extraction, local infection, or delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is primarily clinical, based on visual examination and patient history. Imaging studies, such as panoramic radiographs or CT scans, may be used to assess the extent of bone involvement. The multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research aids in distinguishing ONJ from other jaw pathologies.

Fosamax Pharmacology and Reported Adverse Effects

Fosamax (alendronate sodium) works by inhibiting osteoclast-mediated bone resorption, which reduces bone turnover. While this mechanism is beneficial for increasing bone density in osteoporosis, it can also suppress normal bone remodeling in the jaw. The time to onset of symptoms after starting Fosamax varied from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The exact mechanism by which Fosamax contributes to ONJ is not fully understood, but several pathways are proposed. Bisphosphonates accumulate in bone and inhibit osteoclast activity, leading to suppressed bone turnover. In the jaw, which has high bone turnover rates, this suppression may impair the ability to repair microdamage and respond to infection or trauma. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone. The multiscale characterization of jawbone provides information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique properties of jawbone that may predispose it to ONJ.

Risk Factors and Adequacy of Warnings

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical judgment of the treating physician and/or oral surgeon should guide the management plan of each patient based on individual benefit/risk assessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who develop ONJ while on bisphosphonate therapy should receive care by an oral surgeon (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warnings in the Fosamax label adequately describe these risks and management strategies.

Causation-Related Considerations for Affected Patients

Establishing causation between Fosamax use and ONJ requires consideration of the timeline of exposure and symptom onset. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset of patients had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). These patterns support a causal relationship. However, ONJ can also occur spontaneously, and other risk factors such as cancer, chemotherapy, and dental procedures may contribute. The retrospective case series on bisphosphonate-related ONJ in 20 cats highlights that this presentation is rare in cats but more commonly published in human literature (https://pubmed.ncbi.nlm.nih.gov/39247125/). This study aims to make this a more globally known entity with subsequent improved prognosis (https://pubmed.ncbi.nlm.nih.gov/39247125/). For affected patients, a thorough evaluation of all risk factors and the temporal relationship with Fosamax use is necessary.

Timeline Between Exposure and Documented Harm

The timeline between Fosamax exposure and the development of ONJ can vary widely. Symptoms may appear as early as one day after starting the drug or may take several months to develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that the harm is related to ongoing drug exposure and that cessation can mitigate risk.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ)?

Osteonecrosis of the jaw is a condition characterized by exposed bone in the oral cavity that does not heal within eight weeks. It can occur spontaneously or after dental procedures, and is associated with bisphosphonate use including Fosamax. Diagnosis is clinical, often supported by imaging. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

How does Fosamax cause osteonecrosis of the jaw?

Fosamax inhibits osteoclast activity, reducing bone turnover. In the jaw, which has high turnover, this can impair repair of microdamage and response to infection or trauma. Anti-angiogenic effects may also reduce blood supply. The exact mechanism is not fully understood. (https://pubmed.ncbi.nlm.nih.gov/40345077/)

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, chemotherapy, corticosteroids, poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures, and longer duration of bisphosphonate use. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

How long after starting Fosamax can ONJ develop?

Symptoms can appear as early as one day or take several months after starting Fosamax. The risk increases with longer exposure. Discontinuation may reduce risk for those needing dental procedures. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.